Table 1. Clinical pipeline for anti-BCMA drugs in multiple myeloma
Name |
Lead company |
Partner |
Drug type |
FDA designation |
Phase |
bb2121 |
Celgene |
bluebird bio |
CAR-T |
Orphan, breakthrough |
II |
GSK-2857916 |
GlaxoSmithKline |
Seattle Genetics |
ADC |
Orphan, breakthrough |
II |
AUTO-2 |
Autolus |
n/a |
CAR-T |
n/a |
I/II |
JCARH125 |
Celgene |
n/a |
CAR-T |
Orphan |
I/II |
JNJ-68284528 |
Johnson & Johnson |
Genscript Biotech |
CAR-T |
n/a |
I/II |
AMG 420 |
Amgen |
Boehringer Ingelheim |
BiTE |
Fast track |
I |
Anti-BCMA CAR |
Cellular Biomedicine |
n/a |
CAR-T |
n/a |
I |
bb21217 |
Celgene |
bluebird bio |
CAR-T |
n/a |
I |
CC-93269 |
Celgene |
n/a |
BiTE |
n/a |
I |
FCARH143 |
Celgene |
n/a |
CAR-T |
n/a |
I |
MCARH171 |
Celgene |
n/a |
CAR-T |
n/a |
I |
MEDI22228 |
AstraZeneca |
n/a |
ADC |
n/a |
I |
JNJ-64007957 |
Johnson & Johnson |
n/a |
BiTE |
n/a |
I |
P-BCMA-101 |
Poseida Therapeutics |
n/a |
CAR-T |
RMAT |
I |
PF-06863135 |
Pfizer |
n/a |
BiTE |
n/a |
I |
REGN-5458 |
Sanofi |
Regeneron |
BiTE |
n/a |
I |
ADC = antibody-drug conjugate; BiTE = bispecific T-cell engager; CAR-T = chimeric antigen receptor T-cell; RMAT = Regenerative Medicine Advanced Therapy |
Source: Biomedtracker
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: